

1 Low muscle strength is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes

2

3 Short Title: Muscle strength and cardiac autonomic neuropathy in T2DM

4 Chan-Hee Jung^a, Yoon Young Cho^a, Dug-Hyun Choi^a, Bo-Yeon Kim^a, Sang-Hee Jung^b, Chul-Hee Kim^a, Ji-Oh
5 Mok^{a*}

6 ^a Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University
7 College of Medicine, Bucheon, South Korea

8 ^b Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam, South
9 Korea

10 * Corresponding author:

11 Ji-Oh Mok,

12 Division of Endocrinology and Metabolism, Department of Internal Medicine,

13 Soonchunhyang University College of Medicine,

14 #170 Jomaru-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 420-767, South Korea

15 Tel: 82-32-621-5156

16 Fax: 82-32-621-5016

17 E-mail: hanna@schmc.ac.kr

18 ORCID: Ji-Oh Mok <http://orcid.org/0000-0003-4882-1206>

19 Chan-Hee Jung <http://orcid.org/0000-0001-8988-0187>

20 Word count: 6591

21 Number of figures and tables: 1 figure, 3 tables

22

23

24

25

26

27

28

29

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Abstract**

32 **Background:** Several studies have investigated whether sarcopenia is associated with diabetic microvascular
33 complications, but very few have examined associations between sarcopenia and cardiovascular autonomic
34 neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). Therefore, we investigated associations of
35 muscle strength (handgrip strength [HGS]) and mass (appendicular skeletal muscle mass index [ASMI]) and
36 CAN in patients with T2DM.

37

38 **Methods:** We enrolled 342 T2DM patients (mean age 56.1±11.5 years; 58.2% male) in this retrospective, cross-
39 sectional study. Cardiovascular reflex tests were used to assess CAN according to Ewing's protocol. Relative
40 HGS was determined after normalizing absolute HGS to body weight (HGS/body weight [kg]). We defined low
41 HGS and low ASMI according to a consensus report of the Asian Group for Sarcopenia. Logistic regression
42 analyses were carried out to assess the associations between relative HGS or ASMI quartiles and the presence of
43 CAN in patients with T2DM.

44

45 **Results:** The prevalence rates of CAN, low HGS, and low ASMI in the study subjects were 34.8%, 17.3%, and
46 18.7%, respectively. Low HGS was significantly more prevalent in patients with CAN than those without CAN
47 (23.5% vs. 13.9%, $p=0.025$). The CAN scores were significantly and negatively correlated with relative HGS
48 but not with ASMI. Relative HGS was negative correlated with age, glycated hemoglobin, fasting plasma
49 glucose, hsCRP, body mass index, and HOMA-IR and positively correlated with ASMI. The prevalence of CAN
50 gradually increased with decreasing quartile of relative HGS (28.4% in Q4, 31.8% in Q3, 34.2% in Q2, and 45.3%
51 in Q1, $p=0.02$ for trend). Multivariable-adjusted prevalence ratios (PRs) for CAN, determined by comparing the
52 first, second, and third quartiles with the fourth quartile of relative HGS, were 4.4 with a 95% confidence
53 interval (95% CI) of [1.1 to 17.3], 2.3 (95% CI [0.8 to 6.9]), and 1.2 (95% CI [0.4 to 3.7]), respectively. The
54 prevalence of CAN and the PRs (95% [CI]) for CAN based on ASMI were not statistically significant.

55

56 **Conclusions:** Our findings suggest that low muscle strength rather than low muscle mass was significantly
57 associated with the presence of CAN. Therefore, HGS testing could help identify patients who would benefit
58 from screening for earlier diagnosis of CAN.

59

60 **Keywords:** appendicular skeletal muscle mass; cardiovascular autonomic neuropathy; handgrip strength; muscle

61 mass; muscle strength; type 2 diabetes

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113 **Introduction**

114

115 Cardiovascular autonomic neuropathy (CAN) refers to impaired autonomic control of the heart and vessels and
116 is a common microvascular complication of diabetes.^{1,2} Numerous studies have reported that CAN is associated
117 with life-threatening clinical entities, such as silent myocardial ischemia, coronary artery disease, peri-operative
118 cardiovascular (CV) instability, and cardiac arrhythmia, resulting in increased cardiovascular and all-cause
119 mortality.³⁻⁷ Although there is definitive evidence of the prognostic relevance of CAN, it is underdiagnosed and
120 one of the most overlooked complications of diabetes.^{1,2} Timely diagnosis and efforts to overcome under-
121 diagnosis of CAN are important to avoid serious events. One strategy to overcome under-diagnosis of CAN is to
122 select candidates for active screening based on well known risk factors for the development and progression of
123 CAN in patients with T2DM, such as hyperglycemia, hypertension (HTN), dyslipidemia, and obesity; additional
124 risk factors need to be identified to effectively predict CAN.⁸⁻¹²

125

126 Sarcopenia is defined as the loss of skeletal muscle mass and reduced muscle strength and/or physical
127 performance.¹³ In patients with T2DM, the presence of sarcopenia is receiving growing attention due to its
128 increasing prevalence and the strong negative impact on prognosis.¹⁴ Previous studies revealed a bidirectional
129 relationship between sarcopenia and diabetic vascular complications.¹⁴⁻¹⁶ Several studies have reported
130 associations between sarcopenia and other diabetic microvascular complications^{17,18} but, to our knowledge, there
131 have been very few studies investigating the association between sarcopenia and CAN in T2DM.^{19,20}

132

133 Previous studies have reported subjects with sarcopenia had a greater impairment of cardiac autonomic function
134 and heart rate variability (HRV) than those without sarcopenia.^{21,22} However, most such studies were carried out
135 in obese patients, operated patients, or elderly individuals without DM.^{21,22} Because there have been very few
136 studies evaluating the impact of sarcopenia on CAN in subjects with T2DM, our goal in this study was to
137 investigate the relationships between CAN and two markers of sarcopenia (muscle strength and mass) in Korean
138 patients with T2DM. Association between sarcopenia and CAN could help identify patients who would benefit
139 from active screening for early diagnosis of CAN. Furthermore, interventions to modify sarcopenia may
140 improve the prognosis of patients with CAN.

141

142

143

144 **Methods**

145 **Study subjects**

146 We conducted a retrospective, cross-sectional study of patients with T2DM who were treated at Soonchunhyang
147 University Bucheon Hospital between April 2020 and July 2023. Among patients who were treated at the
148 Endocrinology and Metabolism Clinic, 342 who underwent handgrip strength measurement and bioelectrical
149 impedance analysis (BIA) and were assessed for CAN were enrolled in this study. The study protocol was
150 approved by the Institutional Review Board (IRB) of Soonchunhyang University School of Medicine, Bucheon
151 Hospital (IRB number: 2024-04-001). The IRB waived the requirement for informed consent owing to the
152 retrospective design of this medical record review study.

153

154 **Assessment of muscle strength and muscle mass**

155 Muscle strength was evaluated by HGS testing twice for each hand using a Smedley analog hand dynamometer
156 (No. 04125; MIS, Tokyo, Japan) in a standing position, and the maximum value was used in the analyses.
157 Relative HGS was calculated as absolute HGS (kg) divided by body weight to reduce the impact of body size.²³
158 We used bioimpedance analysis (BIA) to assess muscle mass. Appendicular skeletal muscle mass (ASM) was
159 calculated by summing the lean mass in the arms and legs, which primarily represents skeletal muscle mass. The
160 ASM index (ASMI) was calculated as ASM divided by height squared (ASM/Ht^2 ; kg/m^2). According to the
161 consensus report of the Asian Working Group for Sarcopenia, we defined low muscle strength as HGS <26 kg
162 for men and <18 kg for women and defined low muscle mass as ASMI <7 kg/m^2 in men and <5.7 kg/m^2 in
163 women.¹³ Subjects were divided into relative HGS quartiles or ASMI quartiles for statistical analysis.

164

165 **Diagnosis of CAN**

166 Autonomic function tests (AFT) were performed by a single operator in the morning in a quiet room, and the
167 results were analyzed by one investigator. The subject was instructed to avoid consuming food, coffee, alcohol,
168 and smoking for at least 2 h before the tests. The presence of CAN was assessed using the five standard non-
169 invasive cardiovascular reflex tests (CVRTs) proposed by Ewing and Clarke more than 30 years ago [24] and
170 that are now considered the cornerstone of diagnosis. The five CVRTs are the heart rate (HR) responses to (i)
171 deep breathing (beat-to-beat variation), (ii) standing (30:15 ratio), and (iii) the Valsalva maneuver and the blood
172 pressure (BP) response to (iv) standing and (v) a sustained handgrip. The CVRTs were assessed automatically
173 from electrocardiography recordings using the DICAN evaluation system (Medicore Co., Ltd., Seoul, Korea).

174 Each CVRT was assigned a score of 0, 0.5, or 1 depending on whether the result was normal, borderline, or
175 abnormal, respectively as previously described by Bellavere et al.²⁵ The presence of CAN was quantified by
176 summing the scores of the five tests, and was defined as the presence of at least two abnormal tests or an
177 autonomic neuropathy score ≥ 2 .

178

179 **Other covariates**

180 Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index (BMI) was
181 calculated as body weight (kg) divided by height squared (meters). Blood samples were collected after overnight
182 fasting. Glycated hemoglobin (HbA1c) was measured by ion-exchange high-performance liquid
183 chromatography (Bio-Rad, Hercules, CA, USA) using a methodology aligned with the Diabetes Control and
184 Complications Trial and National Glycohemoglobin Standardization Program standards. Estimated glomerular
185 filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease study equation, and the
186 urine albumin-to-creatinine ratio (ACR) was assessed in spot urine specimens. Insulin resistance (IR) status was
187 evaluated using the formula for the homeostasis model assessment–insulin resistance (HOMA-IR) index:
188 $(\text{fasting insulin } [\mu\text{IU/mL}] \times \text{fasting plasma glucose } [\text{mmol/L}]) / 22.5$.

189

190 **Statistical analysis**

191 Data are reported as mean \pm standard deviation (SD) or median (interquartile range) for continuous variables or
192 as number of subjects (percentage) for categorical variables. The baseline characteristics of the study subjects
193 according to the presence of CAN were compared using two-sample independent *t* tests for continuous variables
194 and Chi-square tests for categorical variables as appropriate. To evaluate linear trends in the prevalence of CAN
195 according to relative HGS and ASMI quartiles, *p* values were calculated using linear-by-linear association tests
196 for categorical variables. Correlations between relative HGS, ASMI, and CAN score were assessed using the
197 Spearman's rank correlation coefficient. Multivariate logistic regression analyses were performed to estimate
198 the independent effects of relative HGS or ASMI quartile on the prevalence ratios (PRs) of CAN after
199 adjustment for possible confounding factors (age, sex, BMI, current alcohol drinking, current smoking, duration
200 of diabetes, HTN, HbA1c, triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), eGFR, ACR, high-
201 sensitivity c-reactive protein (hsCRP), HOMA-IR, beta-blockers, angiotensin-receptor blockers (ARBs),
202 sodium-glucose cotransporter 2 inhibitors (SGLT2is), and insulin treatment). Skewed variables (hsCRP, TG, and
203 ACR) were transformed logarithmically to improve normality before analyses. P values less than 0.05 were

204 considered significant. All statistical analyses were performed using SPSS 19.0 statistical software (IBM Corp.,
205 Armonk, NY, USA).

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234 **Results**

235 **General characteristics of the subjects**

236 The general characteristics of the study subjects are presented in Table 1. A total of 342 Korean T2DM patients
237 (199 male, 143 female, mean age 56.1 ± 11.5 years) was enrolled in this retrospective, cross-sectional study. The
238 CAN prevalence was 34.8% (n=119), and the mean BMI and duration of DM were 25.7 kg/m^2 and 7.0 years,
239 respectively. The mean HbA1c of the study population was 8.5%, and the proportions of subjects treated with
240 oral hypoglycemic agents (OHA) or insulin were 65.2% and 15.8%, respectively. The mean HGS and ASMI
241 were 29.7 kg and 7.3 kg/m^2 , respectively, and the proportion (number) of patients with low HGS and low ASMI
242 were 17.3% (n=59) and 18.7% (n=64).

243

244 **Comparisons of clinical characteristics according to the presence or absence of CAN**

245 The general characteristics of subjects according to the presence or absence of CAN are presented in Table 1.
246 The mean HGS and relative HGS were lower in subjects with CAN than in subjects without CAN (27.6 kg vs.
247 30.8 kg, $p=0.004$, 0.40 vs. 0.44, $p=0.006$, respectively). A greater proportion of subjects with CAN had low
248 HGS than those without CAN (23.5% vs. 13.9%, $p=0.025$). There were no significant differences in mean age,
249 duration of DM, BMI, HTN, glucose parameters, lipid profiles, eGFR, ACR, hsCRP, and HOMA-IR according
250 to the presence or absence of CAN. In addition, there were no significant differences in treatment modalities
251 such as insulin or OHA between subjects with CAN and those without CAN. The proportion of subjects using
252 SGLT2is or beta-blockers was significantly larger in subjects without CAN than those with CAN (17.5% vs.
253 7.6%, $p=0.004$, 6.3% vs. 1.7, $p=0.011$, respectively), and use of ARB was more prevalent in those with CAN
254 than those without CAN (30.3 % vs. 27.4%, $p=0.042$).

255

256 **Prevalence of CAN according to relative HGS and ASMI quartiles**

257 The prevalence of CAN according to relative HGS and ASMI quartiles is shown in Figure 1. The prevalence
258 declined significantly and progressively from the lowest to highest quartiles of relative HGS (45.3%, 34.2%,
259 31.8%, and 28.4%, respectively, $p=0.02$ for trend; Fig. 1[a]). On the other hand, the prevalence of CAN did not
260 differ from the lowest to highest quartiles of ASMI (36.8%, 35.2%, 34.5%, and 33%, respectively, $p=0.197$ for
261 trend; Fig. 1[b]).

262

263 **Bivariate correlations of CAN score and relative HGS and ASMI with clinical variables**

264 Correlations of CAN score, relative HGS, and ASMI with clinical variables are shown in Table 2. The CAN
265 score showed a significant negative correlation with relative HGS ($r=-0.137$, $p=0.012$). However, there was no
266 significant correlation between CAN score and ASMI. Relative HGS showed significant negative correlations
267 with age, FBS, HbA1c, hsCRP, BMI, and HOMA-IR ($r=-0.116$, $p=0.032$; $r=-0.132$, $p=0.015$; $r=-0.119$, $p=0.03$;
268 $r=-0.201$, $p=0.003$; $r=-0.387$, $p<0.001$; and $r=-0.198$, $p=0.001$, respectively) and a positive correlation with
269 ASMI ($r=0.334$, $p<0.001$). The ASMI was negatively correlated with age and HDL-C ($r=-0.403$, $p<0.001$; $r=-$
270 0.172 , $p=0.002$, respectively) and positively correlated with TG, eGFR, BMI, and HOMA-IR ($r=0.192$, $p<0.001$;
271 $r=0.158$, $p=0.003$; $r=0.439$, $p<0.001$; and $r=0.12$, $p=0.049$, respectively).

272

273 **Associations between CAN and relative HGS or ASMI quartile**

274 Multivariate logistic regression analysis adjusted for confounding variables was used to evaluate the
275 associations between HGS, ASMI, and CAN (Table 3). When the highest relative HGS quartile group was used
276 as a reference in the univariate model, patients in the lowest quartile (Q1) were 2.1-fold more likely to have
277 CAN (OR 2.1; 95% CI [1.1 to 3.9]). This significant association for group Q1 remained even after adjusting for
278 age, duration of DM, HTN, smoking, alcohol, BMI, HbA1c, eGFR, ACR, TC, hsCRP, HOMA-IR, insulin
279 treatment, SGLT2is, beta-blockers, and ARBs (OR 4.4, 95% CI [1.1 to 17.3]). However, there were no
280 significant association between ASMI and CAN in either the unadjusted model or after multivariate adjustment.

281

282

283

284

285

286

287

288

289 Discussion

290 We demonstrated that T2DM patients with low HGS are at a higher risk for the presence of CAN; however, low
291 ASMI was not associated with the presence of CAN. These findings suggest that assessment of muscle strength
292 using HGS could be invaluable in clinical practice to identify high-risk T2DM subjects who require earlier and
293 active screening for CAN.

294

295 There is considerable variation in the reported prevalence of CAN, depending upon the diagnostic criteria, test
296 tool, interpretation of results, and study population.² The prevalence of clinical and subclinical CAN has been
297 estimated to be 20–65% of diabetic patients, which is greater than the prevalence of other diabetic complications.
298 ^{2,26} There is definitive evidence of the prognostic relevance of CAN for all-cause and CV mortality, and the risks
299 are increased even at an asymptomatic stage.²⁷ Despite the importance of early detection of CAN, there are
300 several possible barriers to testing: there is no harmonized definition of CAN, there is a wide variety of tools for
301 assessing CAN, testing can be time-consuming and cumbersome, the results may be difficult to interpret,
302 specific treatments for CAN are lacking, and testing may be considered unnecessary in asymptomatic cases.²⁸
303 Despite these barriers to testing, screening for CAN using Ewing’s tests and HRV may allow diagnosis of at an
304 earlier stage where risk factor modification is possible and reversibility is more likely. The established risk
305 factors for development and progression of CAN are age, duration of diabetes, glycemic control, JTN,
306 dyslipidemia, obesity, and smoking.^{9,11,29} In addition, some studies have suggested glycemic variability, vitamin
307 D, oxidative stress, and chronic inflammation as additional risk factors for CAN.³⁰⁻³²

308

309 There are a few reports in the literature correlating sarcopenia with cardiac autonomic modulation. Early studies
310 suggested that low muscle mass and muscle strength lead to reduced parasympathetic modulation and may be
311 associated with abnormal autonomic modulation. A cross-sectional study of 76 elderly Brazilians showed that
312 greater impairment of HRV was evident in subjects with sarcopenia than in those without sarcopenia.²² In the
313 study, muscular strength was assessed using HGS, muscle mass was assessed using the skeletal muscle index,
314 and cardiac autonomic modulation was evaluated using a heart rate (HR) monitor to record five minutes of
315 successive RR intervals. The analysis of the RR-interval variability was carried out in time and frequency
316 domains. The non-sarcopenia group was that with adequate muscle strength and physical performance but
317 insufficient muscle mass or adequate muscle mass. Sarcopenia was defined as insufficient muscle mass plus

318 insufficient muscle strength and/or poor physical performance. The parameters of autonomic heart rate
319 modulation differed significantly between elderly sarcopenic and non-sarcopenic participants. Elderly
320 sarcopenic participants exhibited lower parasympathetic-associated modulation. Baek et al. investigated the
321 relationship between overweight with low muscle mass and cardiac autonomic function as assessed by HRV in a
322 five-min ECG recording in 1,150 healthy Korean workers.²¹ The overweight group showed reduced
323 parasympathetic modulation compared with the non-overweight group. In addition, the overweight-with-low-
324 muscle-mass group had a lower HRV than the overweight-with-high-muscle-mass group.

325 Hyperinsulinemia and IR can induce the development of a sympathovagal imbalance with SNS predominance³³;
326 hyperinsulinemia-induced SNS activation may then result in further IR and hyperinsulinemia. Weight loss using
327 lifestyle interventions and bariatric surgery may help improve cardiac autonomic function by reducing IR and
328 hyperinsulinemia, leading to a reduction in SNS activation. Several studies have reported that weight reduction
329 through bariatric surgery (BS) improves cardiac autonomic modulation.^{34,35} Furthermore, the presence of low
330 muscle mass and/or strength in the preoperative period has been shown to attenuate the improvement in cardiac
331 autonomic function after BS compared with patients without sarcopenia.³⁶ A recent study by Carvalho et al.
332 showed that women who underwent BS experienced less of an improvement of HRV during the follow-up
333 period among women with low muscle mass and /or handgrip strength.³⁶

334

335 To the best of our knowledge, there have been few studies assessing associations of sarcopenia and CAN in
336 T2DM, and the findings were not consistent with those of our study.^{19,20} The primary aim of the study by Mikura
337 et al. was to investigate the association between sarcopenia and severity of diabetic peripheral neuropathy (DPN)
338 in 261 Japanese patients (median age; 67 years, median duration of DM; 10 years).¹⁹ They also evaluated the
339 association of autonomic neuropathy and sarcopenia. The coefficient of variation of the R-R interval was
340 assessed using ECG as a marker of autonomic function, and autonomic neuropathy was noted if CV R-R was
341 lower than the reference ranges. In addition, sarcopenia was identified based on the AWGS 2019 diagnostic
342 criteria, consistent with our current study. The Mikura et al. study showed that neither autonomic neuropathy nor
343 DPN was significantly correlated with sarcopenia. Another study by Ozgur Y et al. examined the relationships
344 between several diabetic neuropathy subtypes and low muscle mass/low muscle strength in a cross-sectional
345 study of 602 diabetic patients (mean age; 60.2 years).²⁰ In the study, diabetic neuropathy was classified into
346 subtypes of diabetic sensorimotor polyneuropathy or diabetic autonomic neuropathies (DAN), and DAN was
347 further subclassified into four subgroups of gastrointestinal autonomic neuropathy, genitourinary autonomic

348 neuropathy, sudomotor autonomic neuropathy, and CAN. The Ozgur study used HR while sitting, HR response
349 to standing, and BP response to standing to diagnose CAN in the presence of abnormality in two of three tests.
350 When the DAN sub-groups were considered, the prevalence of CAN did not differ significantly between the
351 sarcopenic and non-sarcopenic groups. In addition, there was no significant association between CAN and low
352 muscle mass or low muscle strength in logistic regression analyses. Specifically, the prevalence of diabetic
353 neuropathy in the low muscle strength group was greater than in the low muscle mass group. They found that
354 although the skeletal muscle mass index was higher in low muscle strength when compared to low muscle mass
355 group, their muscle qualities were much lower in low muscle strength. The latter finding suggests that loss of
356 muscle strength is more important than loss of muscle mass in terms of the prognosis of diabetic neuropathy.
357 In our study, subjects with low HGS had a greater CAN prevalence than subjects with low ASMI (47.5% vs.
358 31.2%, data not shown). The prevalence of CAN increased progressively with decreasing quartile of relative
359 HGS, and the lowest quartile of relative HGS was significantly associated with the PR of CAN. However, the
360 prevalence of CAN and PRs for CAN based on ASMI were not significant. Our findings study also suggest that
361 muscle strength may be a more useful diagnostic marker of the presence of CAN than muscle mass.

362
363 Most previous studies used HRV derived from ECG recordings as a diagnostic tool for assessment of CAN,
364 whereas there have been no studies investigating the correlation of CAN score based on CVRTs as assessed by
365 Ewing's test and sarcopenia parameters. Although agreement between indices of HRV derived from ECGs and
366 CVRTs has been reported, CVRTs are the gold standard for the diagnosis of CAN.³⁷ We analyzed the
367 correlations of relative HGS, ASMI, and CAN score with clinical parameters and found that relative HGS was
368 significantly and negatively correlated with hsCRP, BMI, HOMA-IR, and glucose parameters. The significant
369 correlations of relative HGS with inflammatory markers, obesity, IR index, and glycemia, all of which are risk
370 factors of CAN, indicate that they contribute to the association between muscle strength and presence of CAN.
371 On the other hand, ASMI was marginally and positively correlated with HOMA-IR, but there was no correlation
372 with hsCRP and glucose parameters. Overall, the CAN score was significantly correlated only with relative
373 HGS not with ASMI. In a Danish multicenter cross-sectional study of T2DM patients, CAN was independently
374 associated with high BP, BMI, and smoking.²⁶ However, in our study, the CAN score was not significantly
375 correlated with duration of diabetes, HbA1c, lipid profile, hsCRP, eGFR, ACR, BMI, or HOMA-IR. Previous
376 studies also reported that age, duration of diabetes, eGFR, BP, lipid profile, and HbA1c did not differ between
377 subjects with and without CAN.³⁰

378

379 Among sarcopenia parameters, muscle strength may represent muscle quality or function. Several studies have
380 reported that low muscle strength, but not muscle mass, is associated with poor physical function and higher
381 mortality.^{23,38}, and that muscle strength more strongly influences various diabetic complications than does
382 muscle mass in patients with T2DM.¹⁷ These findings suggest that measuring muscle mass alone may not be
383 sufficient to predict and protect against DM complications, and preservation of muscle strength may be more
384 important. A previous joint international longitudinal study suggested that HGS is a useful predictor of the risk
385 of CVD and mortality.²³ In addition, a subanalysis of the ORIGIN trial showed HGS to be associated with CVD
386 mortality in patients with T2DM.³⁸

387

388 The mechanisms underlying the association between sarcopenia and cardiac autonomic dysfunction are unclear,
389 but some explanations can be suggested. First, CAN and sarcopenia have multifactorial etiologies and common
390 risk factors. Hyperinsulinemia or IR results in early CAN through the development of a sympathovagal
391 imbalance with SNS activation.^{33,39}, while IR has also been suggested as a main underlying mechanism of
392 sarcopenia. In addition, increased low-grade chronic inflammation is a common feature in patients with
393 sarcopenia and has been associated with decline in muscle mass and strength and reduced HRV.⁴⁰ Second,
394 increased reactive oxygen species and mitochondrial dysfunction can lead to muscle wasting and autonomic
395 dysfunction.^{41,42} Third, the myokine irisin produced by skeletal muscle may serve as an important cross-organ
396 messenger linking skeletal muscle with the brain, adipose tissue, and CV system to integrate energy expenditure
397 with CV activity.⁴³ Irisin controls HR, modulates vagal tone, and promotes CV protection.⁴⁴ Previous studies
398 showed a positive correlation between irisin and HGS in a multivariate analysis.^{45,46} Irisin has been reported to
399 be strongly associated with muscle strength and was recently suggested to be a candidate factor to explain the
400 relationship between muscle strength and parasympathetic tone to the heart, promoting a cardioprotective
401 role.^{43,44} However, since serum irisin was not measured in our study, a direct causal relationship among irisin,
402 muscle strength, and autonomic modulation in patients with T2DM needs to be further examined.

403

404 While there is no conclusive evidence of a successful disease-modifying therapy, multifactorial interventions
405 including glycemic control and weight loss might be effective. In addition, beta blockers and renin-angiotensin-
406 aldosterone system inhibitors are known to have a positive effect on autonomic dysfunction, and emerging data
407 on SGLT2i suggest a modulatory effect on cardiovascular autonomic function.^{47,48} In our current study,

408 adjustment of the models for these medications did not substantially change the results.

409

410 One strength of the present study is that, to the best of our knowledge, it is the first to investigate directly the

411 relationship between HGS and CAN using CVRTs in patients with T2DM. This study also has some limitations.

412 First, we excluded patients with no CVRT, BIA, or HGS results, which led to a small sample size and a potential

413 for selection bias. Second, because of the retrospective, cross-sectional nature of this study, we could not

414 determine causality of the relationship between CAN and sarcopenia. Future prospective or interventional

415 studies are needed to investigate the longitudinal associations among HGS, ASMI, and CAN in a large sample

416 size.

417

418 In conclusion, we demonstrated that HGS was associated with the presence of CAN in Korean patients with

419 T2DM. We also found that ASMI was not associated with the presence of CAN. Low muscle strength is an

420 important cause of morbidity in T2DM and CAN is also a serious complication. In patients with both low

421 muscle strength and CAN, poor quality of life may be expected. Therefore, low muscle strength may be

422 recognized with a simple HGS test performed in clinical practice, allowing early diagnosis of CAN.

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438 **Author contributions**

439 CHJ and JOM contributed to the conception and design of the study; CHJ, YYC, DHC, BYK, and CHK
440 contributed to data collection and management; CHJ, YYC, DHC, BYK, SHJ, CHK, and JOM contributed to
441 acquisition, analysis, or interpretation of the data; CHJ and SHJ contributed to writing the manuscript; JOM
442 contributed to manuscript revision. All authors read and approved the final manuscript.

443

444 **Acknowledgements**

445 This study was supported by a grant from Soonchunhyang University.

446

447 ORCID

448 Chan-Hee Jung <https://orcid.org/0000-0001-8988-0187>

449 Ji-Oh Mok <https://orcid.org/0000-0003-4882-1206>

450

451 **Disclosures**

452 None.

453 **Conflicts of interest**

454 The authors have no conflicts of interest to declare.

455

456 **Ethical statement**

457 The study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital.

458

459 **Informed consent**

460 Not applicable

461

462

463

464

465

466

467 **References**

- 468 1. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation*. 2007;115:387-397
- 469 2. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempner P, Hilsted J,
470 Tesfaye S, Low P, Valensi P; Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic
471 neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. *Diabetes Metab Res Rev*.
472 2011;27:639-653
- 473 3. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and
474 unexpected deaths in male diabetic patients. *Diabetologia*. 1991;34:182-185
- 475 4. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, Heethaar RM, Stehouwer CD.
476 Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes,
477 hypertension, or a history of cardiovascular disease: the Hoorn Study. *Diabetes Care*. 2001;24:1793-1798
- 478 5. Meyer C, Milat F, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and autonomic
479 neuropathy in Type 2 diabetes. *Diabet Med*. 2004;21:746-751
- 480 6. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical
481 manifestations, consequences, and treatment. *J Clin Endocrinol Metab*. 2005;90:5896-5903
- 482 7. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA,
483 Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic
484 dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
485 *Diabetes Care*. 2010;33:1578-1584
- 486 8. Valensi P, Paries J, Attali JR. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes
487 duration, obesity, and microangiopathic complications—the French multicenter study. *Metabolism*.
488 2003;52:815-820
- 489 9. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent
490 large clinical trials. *Curr Diab Rep*. 2014;14:528
- 491 10. Guarino D, Nannipieri M, Iervasi G, Taddei S, Bruno RM. The role of the autonomic nervous system in the
492 pathophysiology of obesity. *Front Physiol*. 2017;8:665
- 493 11. Andersen ST, Witte DR, Fleischer J, Andersen H, Lauritzen T, Jorgensen ME, Jensen TS, Pop-Busui R,
494 Charles M. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2
495 diabetes: ADDITION-Denmark. *Diabetes Care*. 2018;41:2586-2594

- 496 12. Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac Autonomic Neuropathy in
497 Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. *Diabetes Ther.* 2019;10:1995-2021
- 498 13. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al.
499 Asian working group for sarcopenia 2019 consensus update on sarcopenia diagnosis and treatment. *J Am Med*
500 *Dir Assoc.* 2020;21:300-307
- 501 14. Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. *J Am Med*
502 *Dir Assoc.* 2014;15:853-859
- 503 15. Boonpor J, Pell JP, Ho FK, Celis -Morales C, Gray SR. In people with type 2 diabetes, sarcopenia is
504 associated with the incidence of cardiovascular disease: a prospective cohort study from the UK biobank.
505 *Diabetes Obes Metab.* 2024;26:524-531
- 506 16. Xia LF, Li JB, Tian GS, Jiang WR, Li YS, Lin CY, Qiu HN, Wu F, Wang JJ, Li CJ, et al. Effect of sarcopenia
507 on 10-year risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus. *Diabetes*
508 *Metab Syndr Obes.* 2024;17:1621-1634
- 509 17. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K,
510 Yoshimoto T, Ogawa Y. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients
511 with type 2 diabetes: a cross-sectional study. *BMJ Open Diabetes Res Care.* 2017;27:e000404
- 512 18. Wannarong T, Sukpornchairak P, Naweera W, Geiger CD, Ungprasert P. Association between diabetic
513 peripheral neuropathy and sarcopenia: A systematic review and meta-analysis. *Geriatr Gerontol Int.*
514 2022;22:785-789
- 515 19. Mikura K, Kodama E, Lida T, Imai H, Hashizume M, Kigawa Y, Tadokoro R, Sugisawa C, Endo K, Lizaka
516 T, et al. Association between sarcopenia and the severity of diabetic polyneuropathy assessed by nerve
517 conduction studies in Japanese patients with type 2 diabetes mellitus. *J Diabetes Invest.* 2022;13:1357-1365
- 518 20. Ozgur Y, Akin S, Keskin O. Relationship between diabetic neuropathy and sarcopenia. *Prim Care Diabetes.*
519 2019;13:521-528
- 520 21. Baek J, Park D, Kim I, Won JU, Hwang J, Roh J. Autonomic dysfunction of overweight combined with low
521 muscle mass. *Clin Auton Res.* 2013;23:325-331
- 522 22. Freitas VP, Passos RDS, Oliveira AA, Ribeiro IJS, Freire IV, Schettino L, Teles MF, Casotti CA, Pereira R.
523 Sarcopenia is associated to an impaired autonomic heart rate modulation in community-dwelling old adults.
524 *Arch Gerontol Geriatr.* 2018;76:120-124
- 525 23. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the

- 526 measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age*
527 *Ageing*. 2011;40:423-429
- 528 24. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years
529 experience in diabetes. *Diabetes Care*. 1985;8:491-498
- 530 25. Bellavere F, Bosello G, Fedele D, Cardone C, Ferri M. Diagnosis and management of diabetic autonomic
531 neuropathy. *Br Med J (Clin Res Ed)*. 1983;287:61
- 532 26. Fleischer J, Yderstraede K, Gulichsen E, Jakobsen PE, LervangHH, Eldrup E, Nygaard H, Tarnow L,
533 Ejksjaer N. Cardiovascular autonomic neuropathy is associated with macrovascular risk factors in type 2
534 diabetes: new technology used for routine large-scale screening adds new insight. *J Diabetes Sci Technol*.
535 2014;8:874-880
- 536 27. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American
537 Diabetes Association. *Diabetes Care*. 2017;40:136-154
- 538 28. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V,
539 Vinik A, et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and
540 treatments. *Diabetes Care*. 2010;33:2285-2293
- 541 29. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between
542 cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. *J*
543 *Diabetes Complications*. 2011;25:159-167
- 544 30. Gad H, Elgassim E, Mohammed I, Alhaddad AY, Aly HAHZ, Cabibihan J, Al-Ali A, Sadasivuni KK,
545 Petropoulos I, Ponirakis G, et al. Cardiovascular autonomic neuropathy is associated with increased glycemc
546 variability driven by hyperglycemia rather than hypoglycemia in patients with diabetes. *Diabetes Res Clin Pract*.
547 2023;200:110670
- 548 31. Jung CH, Jung SH, Kim KJ, Kim BY, Kim CH, Kang SK, Mok JO. The relationship between vitamin D
549 status and cardiac au-tonomic neuropathy in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res*.
550 2015;12:342-51
- 551 32. Herder C, Schamarek I, Nowotny B, Carstensen-Kirberg M, Straßburger K, Nowotny P, Kannenberg JM,
552 Strom A, Puttgen S, Mussig K, et al; German Diabetes Study Group. Inflammatory markers are associated with
553 cardiac autonomic dysfunction in recent-onset type 2 diabetes. *Heart*. 2017;103:63-70
- 554 33. Saito I, Maruyama K, Eguchi E, Kato T, Kawamura R, Takata Y, Onuma H, Osawa H, Tanigawa T. Low
555 heart rate variability and sympathetic dominance modifies the association between insulin resistance and

- 556 metabolic syndrome—the Toon Health Study. *Circ J*. 2017;81:1447-1453
- 557 34. Kokkinos A, Alexiadou K, Liaskos C, Argyrakopoulou G, Balla I, Tentolouris N, Moysakkis I,
558 Katsilambros N, Vafiadis I, Alexandrou A, et al. Improvement in cardiovascular indices after Roux-en-Y gastric
559 bypass or sleeve gastrectomy for morbid obesity. *Obes Surg*. 2013;23:31-38
- 560 35. Benjamim CJR, Pontes YMM, de Sousa Junior FW, Porto AA, Bueno Junior CR, Marcelino da Silva AA,
561 Ferro Cavalcante TC, Garner DM, Valenti VE. Does bariatric surgery improve cardiac autonomic modulation
562 assessed by heart rate variability? A systematic review. *Surg Obes Relat Dis*. 2021;17:1497-1509
- 563 36. Crispim Carvalho NN, Baccin Martins VJ, da Nóbrega VA, de Arruda Neta ADCP, Cavalcante da Fonseca
564 LA, Bandeira F, de Brito Alves JL. Effects of Preoperative Sarcopenia-Related Parameters on Cardiac
565 Autonomic Function in Women with Obesity Following Bariatric Surgery: A One-Year Prospective Study.
566 *Nutrients*. 2023;15:2656
- 567 37. Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ and
568 DCCT/EDIC Research Group. Utility of using electrocardiogram measures of heart rate variability as a measure
569 of cardiovascular autonomic neuropathy in type 1 diabetes patients. *J Diabetes Investig*. 2022;13:125-133
- 570 38. Lopez-Jaramillo P, Cohen DD, Gomez-Arbelaez D, Bosch J, Dyal L, Yusuf S, Gerstein HC; ORIGIN trial
571 investigators. Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients:
572 a subanalysis of the ORIGIN trial. *Int J Cardiol*. 2014;174:458-461.
- 573 39. Williams S, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac autonomic neuropathy in
574 obesity, the metabolic syndrome and prediabetes: A narrative review. *Diabetes Ther*. 2019;10:1995-2021
- 575 40. da Fonseca GWP, von Haehling S. Sarcopaenia complicating heart failure. *Eur Heart J Suppl*. 2019;21:L20–
576 L23
- 577 41. Tse G, Yan BP, Chan YW, Tian XY, Huang Y. Reactive oxygen species, endoplasmic reticulum stress and
578 mitochondrial dysfunction: The link with cardiac arrhythmogenesis. *Front Physiol*. 2016;7:313
- 579 42. Abrigo J, Elorza A, Riedel CA, Vilos C, Simon F, Cabrera D, Estrada L, Cabello-Verrugio C. Role of
580 oxidative stress as key regulator of muscle wasting during cachexia. *Oxid Med Cell Longev*. 2018;2018:2063179
- 581 43. Zhang W, Chang L, Zhang C, Zhang R, Li Z, Chai B, Li J, Chen E, Mulholland M. Central and peripheral
582 irisin differentially regulate blood pressure. *Cardiovasc Drugs Ther*. 2015;29:121-127
- 583 44. Brailoiu E, Deliu E, Sporici RA, Brailoiu GC. Irisin evokes bradycardia by activating cardiac-projecting
584 neurons of nucleus ambiguus. *Physiol Rep*. 2015;3:e12419
- 585 45. Munoz IYM, Romero ESC, Padilla TC, Benitez JGS, Romero MSC, Morales LPM, Bravo GGH, Garcia JGG.

586 Association of irisin serum concentration and muscle strength in normal-weight and overweight young women.

587 *Front Endocrinol.* 2019;10:621

588 46. Planella-Farrugia C, Comas F, Sabater-Masdeu M, Moreno M, Moreno-Navarrete JM, Rovira O, Ricart W,

589 Fernandez-Real JM. Circulating irisin and myostatin as markers of muscle strength and physical condition in

590 elderly subjects. *Front Physiol.* 2019;10:871

591 47. Colle SD, Morello F, Rabbia F, Milan A, Naso D, Puglisi E, Mulatero P, Veglio F. Antihypertensive drugs

592 and the sympathetic nervous system. *J Cardiovasc Pharmacol.* 2007;50:487-496

593 48. Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. *J Cardiol.*

594 2018;71:471–6

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635
636
637
638
639
640
641
642
643
644
645

Table 1. General characteristics of study patients according to the presence of CAN

	Total	CAN (-)	CAN (+)	P-value
Frequency, n (%)	342	223 (65.2%)	119 (34.8%)	
Age (years)	56.1±11.5	55.4±11.6	57.4±11.3	0.123
Duration of diabetes	7.0±7.5	6.6±7.5	7.9±7.5	0.149
Sex (men), n (%)	199 (58.2%)	137 (61.4%)	62 (52.1%)	0.096
HbA1C (mmol/mol)	69.4±2.0	67.2±1.0	72.7±3.0	0.070
FPG (mmol/L)	8.42±2.89	8.26±2.73	8.72±3.15	0.185
Total cholesterol (mg/dL)	159±47	156±45	164±51	0.140
TG (mg/dL)	125 (90–178)	122 (90–173)	127 (91–195)	0.191
HDL-C (mg/dL)	47±11	47±11	47±11	0.778
LDL-C (mg/dL)	87±35	85±34	90±37	0.191
HTN, n (%)	119 (34.8%)	74 (33.6%)	45 (40.2%)	0.240
hsCRP (mg/L)	0.08 (0.04–0.22)	0.08 (0.04–0.23)	0.08 (0.04–0.21)	0.593
ACR	1.2 (0.6–3.7)	1.1 (0.6–3.2)	1.4 (0.6–6.2)	0.905
eGFR	90.1±17.0	90.6±17.4	87.2±20	0.096
HOMA-IR	2.9 (1.7–4.8)	2.8 (1.6–4.4)	3.2 (1.8–5.1)	0.095
BMI	25.7±4.0	25.7±3.9	25.8±4.1	0.703
HGS (kg)	29.7±9.6	30.8±9.4	27.6±9.6	0.004
Relative HGS	0.43±0.12	0.44±0.11	0.40±0.12	0.006
ASMI (kg/m ²)	7.3±1.0	7.4±1.1	7.2±1.0	0.164
Low HGS, n (%)	59 (17.3%)	31 (13.9%)	28 (23.5%)	0.025
Low ASMI, n (%)	64 (18.7%)	44 (19.7%)	20 (16.8%)	0.509
Smoking, n (%)	89 (26%)	63 (28.3%)	26 (21.8%)	0.328
Alcohol, n (%)	110 (32.2%)	69 (30.9%)	41 (34.5%)	0.455
Diabetic retinopathy, n (%)	64 (25.4%)	37 (22.8%)	27 (30%)	0.211
DPN, n (%)	112 (41.8%)	66 (37.9%)	46 (48.9%)	0.081
OHA, n (%)	223 (65.2%)	149 (68%)	74 (66.1%)	0.718
Metformin, n (%)	213 (62.3%)	145 (65%)	68 (57.1%)	0.077
DPP4I, n (%)	132 (38.6%)	82 (36.8%)	50 (42%)	0.026
SGLT2I n, (%)	48 (14%)	39 (17.5%)	9 (7.6%)	0.004
GLP1RA n, (%)	17 (5%)	12 (5.4%)	5 (4.2%)	0.056
Insulin, n (%)	54 (15.8%)	34 (15.2%)	20 (16.8%)	0.051
ARB	97 (28.4%)	61 (27.4%)	36 (30.3%)	0.042
Beta blockers	16 (4.7%)	14 (6.3%)	2 (1.7%)	0.011

646 Data are reported as mean ± standard deviation (SD) or median (interquartile range) or as number of subjects
647 (percentage).

648 ACR, Albumin/creatinine ratio; ARB, angiotensin receptor blocker; ASMI, appendicular skeletal muscle index;
649 BMI, body mass index; CAN, cardiovascular autonomic neuropathy; DPN, diabetic peripheral neuropathy;
650 DPP4I, dipeptidyl peptidase-4 inhibitor; FPG, fasting plasma glucose; GLP1RA, glucagon like peptide-1
651 receptor agonist; HbA1C, glycated hemoglobin; HDL-C, high density lipoprotein-cholesterol; HGS, handgrip
652 strength; HOMA-IR, homeostasis model assessment–insulin resistance; hsCRP, high-sensitivity c-reactive
653 protein; LDL-C, low density lipoprotein-cholesterol; OHA, oral hypoglycemic agent; SGLT2I, sodium-glucose
654 cotransporter 2 inhibitor; TG, triglyceride

655
656

657
658
659
660
661
662
663
664

Table 2. Correlation analyses for relative HGS, ASMI, and CAN score with clinical variables in total subjects

	Relative HGS	ASMI	CAN Score
	r (p-value)	R (p-value)	R (p-value)
Relative HGS	-	0.334 (<0.001)	-0.137 (0.012)
ASMI	0.334 (<0.001)	-	-0.051 (0.350)
CAN score	-0.137 (0.012)	-0.051 (0.350)	-
Age (years)	-0.116 (0.032)	-0.403 (<0.001)	0.09 (0.097)
Duration of diabetes (years)	-0.01 (0.861)	-0.042 (0.445)	0.061 (0.263)
FPG (mg/dL)	-0.132 (0.015)	-0.021 (0.705)	0.023 (0.668)
HbA1c (%)	-0.119 (0.03)	-0.023 (0.675)	0.102 (0.064)
TC (mg/dL)	-0.06 (0.272)	-0.014 (0.790)	0.006 (0.910)
TG (mg/dL)	-0.103 (0.057)	0.192 (<0.001)	-0.033 (0.542)
HDL-C (mg/dL)	-0.026 (0.640)	-0.172 (0.002)	0.07 (0.215)
LDL-C (mg/dL)	-0.041 (0.461)	0.021 (0.707)	0.008 (0.881)
hsCRP (mg/L)	-0.201 (0.003)	0.047 (0.486)	-0.02 (0.770)
ACR	-0.108 (0.071)	0.017 (0.780)	0.03 (0.620)
eGFR	0.036 (0.513)	0.158 (0.003)	-0.089 (0.101)
BMI	-0.387 (<0.001)	0.439 (<0.001)	-0.003 (0.959)
HOMA-IR	-0.198 (0.001)	0.12 (0.049)	0.027 (0.659)


665 ACR, Albumin/creatinine ratio; ASMI, appendicular skeletal muscle index; BMI, body mass index; CAN,
666 cardiovascular autonomic neuropathy; FPG, fasting plasma glucose; HbA1C, glycated hemoglobin; HDL-C,
667 high density lipoprotein-cholesterol; HGS, handgrip strength; HOMA-IR, homeostasis model assessment–
668 insulin resistance; hsCRP, high-sensitivity c-reactive protein; LDL-C, low density lipoprotein-cholesterol; TG,
669 triglyceride

670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685

686
687
688
689
690
691
692
693
694
695


Fig. 1. The prevalence of CAN in study patients according to quartile of relative HGS or ASMI

[a]



696
697
698

[b]



699

700
701
702
703
704
705
706
707
708

Table 3. Multiple logistic regression analysis of the association of sarcopenia with presence of CAN

	Model 1		Model 2	
	PRs (95% CI)	P-value	PRs (95% CI)	P-value
Relative HGS				
Quartile 1	2.1 [1.1, 3.9]	0.021	4.4 [1.1, 17.3]	0.033
Quartile 2	1.3 [0.7, 2.5]	0.422	2.3 [0.8, 6.9]	0.126
Quartile 3	1.2 [0.6, 2.2]	0.622	1.2 [0.4, 3.7]	0.731
Quartile 4	1 [Reference]		1 [Reference]	
ASMI				
Quartile 1	1.2 [0.6, 2.2]	0.601	1.4 [0.3, 6.7]	0.648
Quartile 2	1.1 [0.6, 2.1]	0.75	1.2 [0.3, 5.3]	0.775
Quartile 3	1.1 [0.6, 2.0]	0.831	1.1 [0.3, 4.0]	0.835
Quartile 4	1 [Reference]		1 [Reference]	

709